Evidence map›Paper›PMID 41733380›Full record

ArticleJournal of clinical microbiology2026

Accuracy of nanopore-based targeted next-generation sequencing assay for detection of

Zeliang Yang, Zichun Ma, Zubi Liu, Peibo Li, Yuqin Liu, Long Cai, Biyi Su, Dan Li, Lele Wang, Lu Cui and 7 more

Abstract readMulticenter StudyEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Zeliang Yang *Beijing Key Laboratory for Key Technologies in Tuberculosis Prevention and Control, Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.ORCID 0000-0002-1737-7299
Zichun Ma *Beijing Key Laboratory for Key Technologies in Tuberculosis Prevention and Control, Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Zubi Liu *Zhejiang Key Laboratory of Digital Technology in Medical Diagnostics, Dian Diagnostics Group Co., Ltd., Hangzhou, Zhejiang, China.
Peibo Li *Department of the Fifth Tuberculosis, Chongqing Public Health Medical Center, Chongqing, China.
Yuqin Liu *Infectious Disease Hospital of Heilongjiang Province, Harbin, Heilongjiang, China.
Long Cai *Department of Clinical Laboratory, Hangzhou Red Cross Hospital, Hangzhou, China.ORCID 0000-0001-6585-2448
Biyi Su *Department of Clinical Laboratory, Guangzhou Chest Hospital, Guangzhou, China.
Dan Li *Zhejiang Key Laboratory of Digital Technology in Medical Diagnostics, Dian Diagnostics Group Co., Ltd., Hangzhou, Zhejiang, China.
Lele WangDepartment of the Fifth Tuberculosis, Chongqing Public Health Medical Center, Chongqing, China.
Lu CuiDepartment of the Fifth Tuberculosis, Chongqing Public Health Medical Center, Chongqing, China.
Rui ShaoInfectious Disease Hospital of Heilongjiang Province, Harbin, Heilongjiang, China.
Dapeng FanDepartment of Clinical Laboratory, Hangzhou Red Cross Hospital, Hangzhou, China.
Yaoju TanDepartment of Clinical Laboratory, Guangzhou Chest Hospital, Guangzhou, China.ORCID 0000-0001-5219-1265
Dan ShenZhejiang Key Laboratory of Digital Technology in Medical Diagnostics, Dian Diagnostics Group Co., Ltd., Hangzhou, Zhejiang, China.
Hong ShiZhejiang Key Laboratory of Digital Technology in Medical Diagnostics, Dian Diagnostics Group Co., Ltd., Hangzhou, Zhejiang, China.
Liang LiBeijing Key Laboratory for Key Technologies in Tuberculosis Prevention and Control, Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.ORCID 0000-0001-5212-5890
Yu PangBeijing Key Laboratory for Key Technologies in Tuberculosis Prevention and Control, Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.ORCID 0000-0001-6803-9807

Funding

Beijing Municipal Science & Technology Commission Z221100007422056 and Z221100007422064Beijing Tongzhou District Science and Technology Commission KJ2024CX028State Key Research Development Program of China 2022YFC2305003
6 · The paper itself

Abstract

Tuberculosis (TB) remains the leading cause of mortality caused by a single infectious agent. Targeted next-generation sequencing (tNGS) has become a promising molecular method for TB diagnosis, but its accuracy and application for non-sputum specimens still remain unexplored. In this multicenter prospective lab-developed assay, 701 participants from five designated TB hospitals from different provinces in China were recruited. Non-sputum specimens were collected for tNGS, Xpert

Indexed as

Drug Resistance, BacterialHigh-Throughput Nucleotide SequencingMolecular Diagnostic TechniquesMycobacterium tuberculosisTuberculosisAdultAgedAntitubercular AgentsChinaFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedProspective StudiesSensitivity and SpecificityAntitubercular Agentsdiagnosisdrug susceptibilitynanopore-based targeted next-generation sequencingnon-sputum specimenstuberculosis

Identifiers

PMID41733380
PMCPMC13059801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.